Spots Global Cancer Trial Database for Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Official Title: Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Study ID: NCT01459159
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Bay Area Cancer Research Group, Concord, California, United States
University of Colorado, Aurora, Colorado, United States
SIU School of Medicine, Simmons Cancer Institute, Springfield, Illinois, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Columbia University, New York, New York, United States
The West Clinic, Memphis, Tennessee, United States
Vanderbilt University, Nashville, Tennessee, United States
Contact Details
Name: Gail L Brown, MD
Affiliation: Telik
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
